Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LONA | 3 | neutral | 2/10 | Natalie C. Holles filed an initial statement of beneficial ownership (Form 3) with the SEC, indicating her status as an | May 7, 2026 |
| CPRX | DEFA14A | bullish | 8/10 | Catalyst Pharmaceuticals (CPRX) filed additional proxy soliciting materials for its pending acquisition by Angelini Phar | May 7, 2026 |
| KALA | S-3 | neutral | 2/10 | KALA BIO filed an S-3 shelf registration to issue an unlimited amount of senior and subordinated debt securities. The fi | May 7, 2026 |
| JBIO | S-3 | bearish | 7/10 | Jade Biosciences filed an S-3 resale registration for up to 39.5M shares held by selling stockholders (57.9% of outstand | May 7, 2026 |
| SHPH | 8-K | bearish | 8/10 | Shuttle Pharmaceuticals completed its merger with United Dogecoin Inc., transforming into a crypto mining company. Exist | May 7, 2026 |
| NATR | 8-K | bullish | 6/10 | NATR reported strong Q1 2026 results with revenue up 9% YoY to $122.9M and GAAP EPS of $0.29, a 45% beat vs consensus of | May 7, 2026 |
| ALEC | 8-K | bearish | 6/10 | Alector entered into an at-the-market (ATM) equity offering agreement with TD Cowen to sell up to $125M of common stock, | May 7, 2026 |
| JBIO | S-3 | bearish | 7/10 | Jade Biosciences filed a $600M universal shelf registration statement, including a $200M at-the-market (ATM) equity offe | May 7, 2026 |
| ELOX | S-1 | neutral | 5/10 | Eloxx Pharmaceuticals filed an S-1 registration statement for a proposed public offering of common stock and pre-funded | May 7, 2026 |
| FDMT | S-3 | neutral | 4/10 | 4DMT filed a $400M shelf registration (S-3) to replace an expiring shelf, with $200M carried forward and $200M newly reg | May 7, 2026 |
| CSTL | 144 | neutral | 3/10 | CEO Derek Maetzold filed Form 144 indicating intent to sell 14,008 shares (~$269.5K) under a Rule 10b5-1 trading plan ad | May 7, 2026 |
| RCKTW | 8-K | mixed | 6/10 | Rocket Pharmaceuticals reported Q1 2026 net loss of -$47.6M (-$0.42/share), improving from -$61.3M (-$0.56) a year ago. | May 7, 2026 |
| PRFX | 6-K | bearish | 7/10 | PRF Technologies entered into a standby equity purchase agreement with Yorkville for up to $10 million, pricing at 97% o | May 7, 2026 |
| RAPP | 144 | neutral | 3/10 | Third Rock Ventures V, L.P., a 10% stockholder, filed a Form 144 indicating intent to sell 271,495 shares of Rapport The | May 7, 2026 |
| GPCR | 8-K | mixed | 6/10 | Structure Therapeutics reported Q1 2026 net loss of $76.0M, widening from $46.8M a year ago, while announcing positive P | May 7, 2026 |
| INAB | 8-K | neutral | 3/10 | IN8bio reported Q1 2026 net loss of $5.1M ($0.26 per share), beating the -$0.59 consensus, driven by lower R&D expenses. | May 7, 2026 |
| IRD | PRESS-RELEASE | bullish | 6/10 | Opus Genetics reported positive clinical data for its LCA5 gene therapy (OPGx-LCA5) showing over 30-fold improvement in | May 7, 2026 |
| NKTR | 8-K | neutral | 4/10 | Nektar Therapeutics reported Q1 2026 revenue of $10.9M (+3.8% YoY) and a net loss of $44.9M ($1.82 per share), improving | May 7, 2026 |
| CORT | CLUSTER | neutral | 3/10 | Corcept Therapeutics' CEO and CDO sold $3.04M in open-market shares within a week of the Q1 earnings release. The trades | May 7, 2026 |
| GOVX | 8-K | bearish | 7/10 | GeoVax entered into a warrant inducement agreement with institutional holders to immediately exercise existing warrants | May 7, 2026 |
| TECX | 8-K | bearish | 5/10 | Tectonic Therapeutic reported Q1 2026 net loss of $25.2M (-$1.34/share), missing consensus of -$1.16 by 15.5%. R&D spend | May 7, 2026 |
| CGTX | 8-K | neutral | 5/10 | Cognition Therapeutics reported Q1 2026 net loss of $4.6M ($0.05/share), narrower than the $8.5M loss in Q1 2025, driven | May 7, 2026 |
| STOK | 8-K | neutral | 4/10 | Stoke Therapeutics reported Q1 2026 net loss of $50.0M ($0.79 per share) vs net income of $112.9M in Q1 2025, which incl | May 7, 2026 |
| NXTC | 8-K | neutral | 3/10 | NextCure reported Q1 2026 net loss of $9.8M ($1.87 per share), in line with consensus of $1.85. Cash burn continues with | May 7, 2026 |
| JANX | 8-K | neutral | 4/10 | Janux Therapeutics reported Q1 2026 EPS of -$0.39, a 22% beat vs consensus of -$0.50, driven by a $35M BMS milestone pay | May 7, 2026 |
| JBIO | 8-K | neutral | 4/10 | Jade Biosciences reported Q1 2026 EPS of -$0.57, missing consensus of -$0.52 by 9.6%. Net loss widened to $40.4M from $3 | May 7, 2026 |
| CRNX | 8-K | neutral | 5/10 | Crinetics reported Q1 2026 revenue of $10.7M (vs $0.4M YoY), driven by $10.3M in PALSONIFY net product revenue, nearly d | May 7, 2026 |
| PRTA | 8-K | bullish | 8/10 | Prothena reported a transformative Q1 2026: net income of $32.7M (diluted EPS $0.60) vs. consensus loss of -$0.31, drive | May 7, 2026 |
| DNLI | PRESS-RELEASE | bullish | 7/10 | Denali reported Q1 2026 EPS of -$0.69, a slight beat vs consensus -$0.71, but the headline is the FDA approval and U.S. | May 7, 2026 |
| SIGA | PRESS-RELEASE | bearish | 6/10 | SIGA reported Q1 2026 total revenues of $6.2M (down 11% YoY) and a net loss of $3.5M vs $0.4M loss a year ago, driven by | May 7, 2026 |